OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision small molecule drugs targeting mutated forms of PI3K alpha, a commonly mutated oncogene in cancer. Their lead candidate, OKI-219, is a highly selective inhibitor of PI3K H1047R being evaluated in the Phase 1 PIKture-01 trial in solid tumors including breast cancer. The company also pursues a pan-mutant PI3K inhibitor and a vascular malformations program.
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-104147 | EDGAR | 103K words |
| 2025-03-10 | 2024-12-31 | 0000950170-25-036252 | EDGAR | 102K words |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038009 | EDGAR | 79K words |
| 2023-03-27 | 2022-12-31 | 0000950170-23-009978 | EDGAR | 95K words |
| 2022-03-23 | 2021-12-31 | 0001558370-22-004158 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0001193125-26-332773 | EDGAR | 58K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269540 | EDGAR | 60K words |
| 2025-08-12 | 2025-06-30 | 0001193125-25-178981 | EDGAR | 59K words |
| 2025-05-06 | 2025-03-31 | 0000950170-25-063970 | EDGAR | 57K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123233 | EDGAR | 51K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096411 | EDGAR | 35K words |
| 2024-05-07 | 2024-03-31 | 0000950170-24-054452 | EDGAR | 52K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062910 | EDGAR | 66K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041302 | EDGAR | 64K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021234 | EDGAR | 63K words |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023250 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016035 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-13 | 0001193125-26-347315 | EDGAR | 1K words |
| 2026-08-04 | 0001193125-26-332809 | EDGAR | 2K words |
| 2026-03-30 | 0001193125-26-130283 | EDGAR | 20K words |
| 2026-03-12 | 0001193125-26-104104 | EDGAR | 2K words |
| 2025-11-06 | 0001193125-25-269652 | EDGAR | 29K words |
| 2025-11-06 | 0001193125-25-269468 | EDGAR | 2K words |
| 2025-08-12 | 0001193125-25-178978 | EDGAR | 2K words |
| 2025-06-26 | 0000950170-25-090403 | EDGAR | 2K words |
| 2025-05-28 | 0000950170-25-078375 | EDGAR | 1K words |
| 2025-05-06 | 0000950170-25-063969 | EDGAR | 2K words |
87 total filings indexed. 60 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001637715 |
| Ticker | OKUR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.onkuretherapeutics.com |
| Listed | 2024-10-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/OKUR (~200 tokens, structured JSON with cryptographic provenance)